Top Markets
#1 Smilek to the Bank Smilek to the Bank +50.56%
#2 Purr Purr +47.15%
#3 Pons Pons +44.66%
#4 Non-Playable Coin Non-Playable Coin +28.34%
#5 StonkBroker StonkBroker +24.99%
#6 Kinetiq Kinetiq +24.50%
#7 ApeX ApeX +24.20%
#8 OriginTrail OriginTrail +19.97%
#9 Pudgy Penguins Pudgy Penguins +19.48%
#10 Grass Grass +19.15%
Coin of the day
Smilek to the Bank Smilek to the Bank
Settings
Language
ENGLISH
Currency
USD
Theme
Kinnate Biopharma Inc. Kinnate Biopharma Inc.

Kinnate Biopharma Inc.

KNTE
Rank in Stocks #21071
Kinnate Biopharma Inc. is a U.S.-based biopharmaceutical company primarily... Kinnate Biopharma Inc. is a U.S.-based biopharmaceutical company primarily focused on identifying and advancing small-molecule drugs that target kinase enzymes to treat cancers defined by specific genetic markers. The company's product pipeline includes: KIN-2787: An inhibitor of rapidly accelerated fibrosarcoma (RAF), currently being developed to treat patients with lung cancer, melanoma, and other forms of solid tumors. KIN-3248: A small-molecule kinase inhibitor designed to counteract cancer-associated genetic mutations in the fibroblast growth factor receptors, specifically FGFR2 and FGFR3. KIN004 Program: This program encompasses early-stage small-molecule research, including a Cyclin-Dependent Kinase 12 (CDK12) inhibitor. Established in 2018, Kinnate Biopharma Inc. maintains its headquarters in San Francisco, California. It was formerly a division of Fount Therapeutics, LLC.
Share Price
$2.65
Last synced: 2024-04-03
Market Cap
$115.71M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Kinnate Biopharma Inc. (KNTE)

Category

Healthcare
Earnings for Kinnate Biopharma Inc. (KNTE)
Earnings in 2026 TTM: 0
According to Kinnate Biopharma Inc. latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Kinnate Biopharma Inc. from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH